Article Text

PO-0836 Determination Of Cognitive Functioning Disorders Incidence In Children With Multiple Sclerosis
  1. K Gücüyener1,
  2. S Soysal1,
  3. U Yilmaz2,
  4. E Demir3,
  5. E Gurkas4,
  6. C Havali3
  1. 1Pediatric Neurology, Gazi University Faculty of Medicine, Ankara, Turkey
  2. 2Pediatric Neurology, Behcet Uz Children’s Hospital Izmir, Izmir, Turkey
  3. 3Pediatric Neurology, Gazi University Faculty of Medicine, Ankara, Turkey
  4. 4Pediatric Neurology, Ankara Childeren’s Oncology Hematology Hospital, Ankara, Turkey

Abstract

Aim Cognitive impairment is seen in patients with paediatric multiple sclerosis in more than 30% of cases. Altered functions with variable frequency are: attention, language (receptive, verbal fluency, naming), visual-spatial and motor functions, spatial memory, executive functions and abstract reasoning. The aim of this study is to determinate the cognitive functions disorders in children with multiple sclerosis.

Methods A total of 21 individuals with paediatric MS (19 girls, 2 boys), ranging from 10–17 years of age (SD=14.90 ± 186) completed initial and follow-up neuropsychological testing at yearly interval. All the patients were given WISC-R, Raven’s Standard Progressive Matrices, Wisconsin Card Sorting, Stroop Test, Line Orientation Test and Verbal Fluency

Results 55% of the patients had Interferon therapy, First attack age was 12.92 ± 2.36, total number of attacks was 2.68 ± 2.19. IQ assessment was as follows: 19.1% (n = 4) borderline, 47.6% (n = 10) average, 33.4% (n = 7) high average. After interferon therapy; patients showed increased reponse time with less mistakes in Stroop test (p < 0.05), there was an increase of vocabulary scores in Verbal Fluency Test, being is still behind the scores of normal children. Visual-spatial perception impairments became evident right after the attacks. Symptoms of depression have been found in the 25% of the patients. There is a correlation (r: 0.82) between tnumber of attacks, cognitive loss, and depression.

Conclusion Cognitive impairment has a negative impact on patient’s life limiting social, academic activities. Early treatment with disease-modifying drugs seems to be advisable in order to prevent or delay the development of cognitive impairment.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.